GET DAILY SIGNALSCAH vs COR: Cardinal Health's +60% Gain Highlights a Clear Edge Over Cencora
Key Takeaways
- Both CAH and COR rank among the top three U.S. pharmaceutical distributors, but their stock paths have moved in notably different directions lately.
- Cardinal Health has shown stronger recent momentum, with shares rising roughly 60% over the past year versus single-digit to low-teens gains for Cencora over a similar period.
- Cencora is focused on a bigger acquisition strategy, highlighted by its up to $2.4 billion deal for American Oncology Network, while Cardinal Health emphasizes faster-growing specialty and management-services areas.
- In my view, based on trend consistency, earnings momentum, and positioning, the AI framework currently favors CAH over COR.
- Additional details are available through resources on CAH Major News, CAH Today's Price Move, COR Major News, and COR Today's Price Move.
Background on These Key Distributors
Cardinal Health and Cencora play central roles in the U.S. pharmaceutical supply chain, handling branded, generic, and specialty medicines for pharmacies, hospitals, and physician practices. Along with McKesson, they dominate domestic drug distribution, making them useful benchmarks for investors interested in healthcare logistics and specialty services. While both operate in the same concentrated industry and navigate similar regulatory pressures, their recent stock results, growth approaches, and market positions have diverged. This comparison matters for those evaluating which large-cap healthcare name offers stronger relative performance and momentum right now.
Cardinal Health's Position and Momentum
Cardinal Health distributes pharmaceuticals and specialty products, manufactures and distributes medical and laboratory items, and offers at-home, nuclear pharmacy, and logistics services. In its latest fiscal year, revenue reached about $254 billion, up 14% year over year, while adjusted EPS increased around 37%. Management expects ongoing double-digit EPS growth, driven by its expanding specialty platform that grew roughly 25% last year and now tops $50 billion in annual revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Investor interest in this specialty-focused shift shows in the market. The stock has climbed approximately 60% over the trailing year and trades at a forward P/E above its own five-year median. Recent moves include expanded nuclear medicine capacity, integration of specialty acquisitions, share buybacks, and a higher dividend. These factors, along with repeated guidance increases, support a positive outlook for CAH.
Cencora's Approach and Recent Results
Cencora, previously known as AmerisourceBergen, ranks as one of the leading U.S. pharmaceutical wholesalers with international distribution and specialty operations such as World Courier and Alliance Healthcare in Europe. Its most recent quarter showed revenue of about $84.8 billion, and it has guided adjusted EPS to $17.70–$17.90 for the fiscal year. A key development is the agreement to buy American Oncology Network for up to $2.4 billion, which strengthens its oncology presence alongside platforms like OneOncology and Retina Consultants of America.
Unlike Cardinal Health, Cencora shares have stayed more range-bound over the trailing year with returns in the single-digit to low-teens range and sit below the 52-week high. Momentum has improved recently on specialty income growth and a larger share repurchase program, yet concerns over customer concentration, biosimilar pricing, and integration costs have limited enthusiasm relative to its peer.
Strategic Differences and Performance Comparison
Both firms lead in pharmaceutical distribution, but their focuses vary. Cencora pursues a more acquisition-heavy specialty model through deals like American Oncology Network to build higher-margin physician and oncology services. Cardinal Health grows its specialty and management-services areas more organically with smaller targeted buys and gains extra balance from medical products and nuclear medicine.
On performance, Cardinal Health has clearly led with its wider margin over the trailing year, backed by faster earnings growth and upward guidance revisions. Cencora brings greater international diversification and a visible M&A pipeline, though its near-term momentum remains softer and its forward P/E sits in a comparable range. Risks differ too: Cencora faces higher customer concentration and integration exposure, while Cardinal Health deals with cost inflation and tariff effects in medical products. Both carry generally positive analyst views, but the market has rewarded Cardinal Health’s earnings path more strongly lately. From what I see, this gap reflects the differing paces of execution.
AI Assessment of the Two Stocks
Considering trend consistency, earnings momentum, and relative positioning, Tickeron’s AI framework currently points to CAH as the stronger choice between the two. Cardinal Health’s firmer price trend, quicker earnings growth, and steady guidance lifts suggest more durable near-term momentum, while Cencora’s modest relative results and heavier reliance on deal-driven catalysts add uncertainty. This remains a data-based probability rather than a firm prediction, and shifts can occur with new reports or events.
Exploring Automated Strategies
I often review Tickeron’s AI Trading Bots to understand how systematic approaches are handling names like these in the current environment. The platform shows various strategies with their performance records and helps evaluate consistency across different market conditions without relying solely on manual analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for CAH turns positive, indicating new upward trend
CAH saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 65 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 32 of 47 cases where CAH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
CAH moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CAH crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 58%.
Following a +2.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAH advanced for three days, in 264 of 396 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 188 of 310 cases where CAH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for CAH moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 22 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 54%.
The Moving Average Convergence Divergence Histogram (MACD) for CAH turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 26 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
CAH broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. CAH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-20.428) is normal, around the industry mean (12.613). CAH has a moderately high P/E Ratio (34.983) as compared to the industry average of (10.633). Projected Growth (PEG Ratio) (1.105) is also within normal values, averaging (2.016). Dividend Yield (0.008) settles around the average of (0.138) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (4.260).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of pharmaceuticals, medical, surgical and laboratory supplies as well as develops drug delivery systems
Industry MedicalDistributors
Advertisement